Despite ADT with ARSis being the primary treatment strategy for a substantial percentage of patients with advanced prostate cancer, resistance to androgen receptor (AR) inhibitors arises in certain cases, particularly those with AR-V7 splice variants, prompting the need for alternative first-line therapeutic approaches [52]. Here, AR is linked to prostate carcinoma.